The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...

• ELRIG Research & Innovation 2025 takes place in London, UK from 10–11 March • Event will focus on ‘Big molecules to big ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...